Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Beth Ward

Sleep Medicine Chesterfield, MO Medical Doctor

NPI 1114945839 CMS profile 1220777

232 S Woods Mill Rd, Sleep Medicine, Chesterfield, MO 63017

Open in the dashboard

General payments

$2,163

22 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Beth Ward of Chesterfield, MO is reported in the CMS Open Payments database as having received $2,163 across 22 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 62nd percentile of Sleep Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $196 7
2024 General $193 4
2023 General $184 2
2022 General $518 3
2021 General $20 1
2020 General $915 2
2019 General $136 3

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Beth Ward
  • Sleep Medicine median
  • Middle half of Sleep Medicine
  • National median

In program year 2025, general payments to Beth Ward were reported at $196. Among 263 Sleep Medicine profiles paid that year, the median was $337 and the middle half received between $114 and $1,241.

Show as a table
Year Beth Ward Sleep Medicine median Middle half National median
2019 $136 $206 $79–$855 $163
2020 $915 $170 $48–$1,437 $114
2021 $20 $178 $53–$1,297 $132
2022 $518 $313 $95–$1,332 $149
2023 $184 $307 $117–$1,081 $160
2024 $193 $308 $100–$1,432 $164
2025 $196 $337 $114–$1,241 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Jazz Pharmaceuticals Inc. $1,543 6 payments
  2. Inspire Medical Systems, Inc. $324 3 payments
  3. Harmony Biosciences LLC $116 3 payments
  4. Resmed Corp $90 4 payments
  5. Merck Sharp & Dohme Corporation $36 2 payments
  6. Itamar Medical Inc $35 3 payments
  7. AbbVie, Inc. $19 1 payment

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $1,263 21 payments
  2. Consulting Fee $900 1 payment
Products named General payments · program years 2019–2025
  1. SUNOSI $1,040 2 payments
  2. Inspire Upper Airway Stimulation System $278 1 payment
  3. XYWAV $240 2 payments
  4. XYREM $140 1 payment
  5. WAKIX $116 3 payments
  6. AIRSENSE Sleep $60 2 payments
  7. INSPIRE $46 2 payments
  8. BELSOMRA $36 2 payments
  9. WatchPATONE $35 3 payments
  10. AirSense Sleep $31 2 payments
  11. Other $38 2 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 19 drugs

Part D claims

542

Median for Sleep Medicine: 173

Drug cost

$184,514

Median for Sleep Medicine: $10,887

Branded share of claims

24.7%

Median for Sleep Medicine: 17.8%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Xywav Sodium,calcium,mag,pot Oxybate Brand 11 $149,235
Belsomra Suvorexant Brand 31 $20,700
Pramipexole Er Pramipexole Di-Hcl Brand 17 $5,429
Zaleplon Generic 61 $1,541
Ropinirole Er Ropinirole Hcl Brand 20 $1,374
Temazepam Generic 32 $1,323
Eszopiclone Generic 43 $1,272
Ropinirole Hcl Generic 40 $727
Azelastine Hcl Generic 36 $661
Zolpidem Tartrate Generic 52 $532

The 10 drugs with the highest cost, of 19 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 723 Part D prescribers listed as Sleep Medicine; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 13 billing codes

Paid by Medicare

$41,641

Medicare's payments for the services billed

Medicare patients

257

Average age 74

Services billed

560

154 women, 103 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 74%
Arthritis 56%
Depression 30%
Ischemic heart disease 28%
Diabetes 24%
Cancer 20%
Atrial fibrillation 18%
Chronic kidney disease 18%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

22 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Sleep Medicine in Missouri

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record